Press Releases
2024 – Press Releases
NetraMark's ai-based clinical solution identifies novel lung and colon cancer biomarkers and patient subpopulations
April 10, 2024 | NetraMark Holdings
NetraMark provides business update and highlights progress
April 02, 2024 | NetraMark Holdings
NetraMark To Present New Data Highlighting The Utility Of Its AI Based Clinical Solution In Identifying Parkinson's Disease Associated Biomarkers At AD/PD™ 2024
February 29, 2024 | NetraMark Holdings
NetraMark To Present New Data Demonstrating The Power Of Its AI Based Technology To De-Risk Neurology Clinical Trials At ISCTM Annual Meeting
February 15, 2024 | NetraMark Holdings
NetraMark's Generative AI Discovers Novel Rare Disease Drug Targets and Unique Patient Subpopulations That Could Substantially Improve Clinical Trial Success Rates
January 16, 2024 | NetraMark Holdings
NetraMark announces shareholder meeting results
April 05, 2024 | NetraMark Holdings
NetraMark signs contract with pharmaceutical company to deliver clinical trial insights regarding efficacy and placebo response
March 12, 2024 | NetraMark Holdings
NetraMark Signs Fourth Contract With Large Biopharmaceutical Company To Enhance Clinical Trial Insights
February 27, 2024 | NetraMark Holdings
NetraMark Announces Launch Of The Netra AI Lab
February 12, 2024 | NetraMark Holdings
Pharmaceutical industry veteran joins NetraMark advisory board
April 04, 2024 | NetraMark Holdings
NetraMark's Ai-based clinical solution identifies parkinson's disease subtypes linked by mitochondrial, microbiome and immune signaling
March 11, 2024 | NetraMark Holdings
NetraMark's AI Based Technology Identifies Significant Drivers Of Efficacy And Placebo Responses And Has Potential To Improve Success Rates For Clinical Trials Of Psychiatric Medications
February 26, 2024 | NetraMark Holdings
NetraMark Signs Third Contract With Large Biopharmaceutical Company to Enhance Clinical Trial Insights
January 30, 2024 | NetraMark Holdings
2023 – Press Releases
NetraMark Signs Two Contracts With Large Biopharmaceutical Company To Enhance Clinical Trial Insights
December 20, 2023 | NetraMark Holdings
NetraMark Signs Master Service Agreement With a Large Biopharmaceutical Company
October 31, 2023 | NetraMark Holdings
NetraMark Private Placement – Press Release Clarification
September 15, 2023 | NetraMark Holdings
NetraMark Announces Shares for Debt Settlement
July 5, 2023 | NetraMark Holdings
NetraMark Closes Second and Final Tranche of Private Placement
June 14, 2023 | NetraMark Holdings
NetraMark Announces Increase to Private Placement Financing
June 6, 2023 | NetraMark Holdings
NetraMark Selects Finn Partners As Its Public Relations Agency Of Record
November 20, 2023 | NetraMark Holdings
NetraMark Signs Master Service Agreement With a Large Biopharmaceutical Company
October 31, 2023 | NetraMark Holdings
NetraMark Announces Private Placement Financing
September 11, 2023 | NetraMark Holdings
NetraMark Enters into Advisor Agreement
June 22, 2023 | NetraMark Holdings
NetraMark Closes First Tranche of Private Placement
June 9, 2023 | NetraMark Holdings
NetraMark Announces Private Placement Financing
June 1, 2023 | NetraMark Holdings
Pharmaceutical Industry Veteran Joins NetraMark as Chief Medical Officer Joins
November 7, 2023 | NetraMark Holdings
NetraMark Closes Private Placement Financing
September 19, 2023 | NetraMark Holdings
Pharmaceutical Industry Veteran Joins NetraMark Advisory Board
July 19, 2023 | NetraMark Holdings
NetraMark Announces Engagement of ARU Global Inc.
June 21, 2023 | NetraMark Holdings
NetraMark Announces Uplist to the OTCQB Market
June 7, 2023 | NetraMark Holdings
NetraMark to Attend American Society of Clinical Oncology Conference in Chicago
June 1, 2023 | NetraMark Holdings